The online edition of ESMO in 30 Seconds from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain discusses AstraZeneca’s success in bladder cancer with Imfinzi, Merck and Eisai’s combo in liver cancer, and Bristol’s approach in lung cancer. AstraZeneca plans to bring data to regulators for approval, Merck and Eisai’s combination reduced the risk of progression or death in liver cancer patients, and Bristol faces criticism for its trial design. Comparison of trial results is common, despite being advised against. Other highlights include a successful trial from iTeos and GSK, a Pfizer antibody for cancer-related weight gain, and potential treatment for HPV-caused anal cancer.
Source link
A win for AstraZeneca in bladder cancer, and more
